Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The stability is led by healthy demand in the domestic and emerging markets
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
A toll-free helpline to be set up to help doctors and patients
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Subscribe To Our Newsletter & Stay Updated